Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Persons with HIV, even those well-treated, are at increased risk for heart disease when
compared to the general population. Two hormones called aldosterone and brain natriuretic
peptide (BNP), which have been shown to be abnormal in HIV, may be associated with
inflammation as well as early changes in structure and function of the heart. This study is
being conducted to evaluate whether therapies to block aldosterone and increase BNP levels
may reduce the burden and progression of heart failure to improve cardiovascular health.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan